Search

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

New initiative elevates the importance of CKD testing

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Cancer

Mental Health

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

What our partners say

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Corporate Social Responsibility | Boehringer Ingelheim US

Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease

Data shows JARDIANCE reduced the risk for new-onset or worsening kidney disease in adults with T2D with established CV disease. View ISI, PI & Med Guide.

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

New initiative elevates the importance of CKD testing

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Cancer

Mental Health

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

FDA accepts sNDA for children/adolescents with fibrosing ILD

What our partners say

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Corporate Social Responsibility | Boehringer Ingelheim US

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Biosimilar Candidate to Humira® Accepted For Review | BI US

Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes